TargetBeta
DDB1
damage specific DNA binding protein 1 · Nucleotide excision repair
2 programs in company-led studies act on DDB1, from 1 company: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Lenalidomiderule | Bristol-Myers Squibb | phase 4 | 10918 running | CRBN, CUL4A, RBX1 | ChEMBL |
| pomalidomiderule | Bristol-Myers Squibb | phase 4 | 5112 running | CRBN, CUL4A, RBX1 | ChEMBL |
Conditions their studies are in
- Multiple Myeloma, 2 programs
- Brain Neoplasms, 1 program
- Hematologic Neoplasms, 1 program
- Lymphoma, Large B-Cell, Diffuse, 1 program
- Lymphoma, Mantle-Cell, 1 program
- Lymphoma, Non-Hodgkin, 1 program
- Myelodysplastic Syndromes, 1 program
- Primary Myelofibrosis, 1 program
- Scleroderma, Systemic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 23, 2026Lenalidomide · Bristol-Myers Squibb · phase 4 · NCT05950165
- Jan 10, 2027pomalidomide · Bristol-Myers Squibb · phase 4 · NCT05519085
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.